Gender | n (%) |
 Female | 233 (98.7) |
 Male >51y | 3 (1.3) |
Age (Female) | |
  < 51y | 93 (40.0) |
  ≥ 51y | 140 (60.0) |
Age | |
 20-29 | 4 (1.7) |
 30-39 | 27 (11.4) |
 40-49 | 55 (23.3) |
 50-59 | 68 (28.8) |
 60-69 | 49 (20.8) |
 70-79 | 25 (10.6) |
 80-89 | 8 (3.4) |
Histopathology | |
 IDC | 197 (83.5) |
 ILC | 16 (6.8) |
 Apocrine Carcinoma | 5 (2.1) |
 Medullary Carcinoma | 3 (1.3) |
 Mucinous Carcinoma | 3 (1.3) |
 Basal-like Carcinoma | 2 (0.8) |
 Tubular Cancer | 2 (0.8) |
 ILC/Tubulolobular | 1 (0.4) |
 Tubulolobular | 1 (0.4) |
 Mixed Carcinoma | 1 (0.4) |
 Papillary Carcinoma | 1 (0.4) |
 Infiltrating | 1 (0.4) |
 Other | 3 (1.3) |
Grade | |
 Invasive grade I | 22 (9.3) |
 Invasive grade II | 65 (27.5) |
 Invasive grade III | 149 (63.1) |
Molecular Subtype | |
 ER+, PR+, HER2+ | 41 (17.4) |
 ER+, PR+, HER2- | 95 (40.3) |
 ER+, PR-, HER2- | 11 (4.7) |
 ER+, PR-, HER2+ | 12 (5.1) |
 ER-, PR+, HER+ | 6 2.5) |
 ER-, PR+, HER2- | 2 (0.8) |
 ER-, PR-, HER2+ | 24 (10.2) |
 ER-, PR-, HER2- | 35 (14.8) |
 Equivocal/Not performed | 10 (4.2) |
Equivocal/Not performed: Lack of result for ER, PR and/or HER2) | |
Disease Outcome/Follow-Up Status | n (%) |
 Died From Disease | 13 (5.5) |
 Died From Other Causes | 8 (3.4) |
 Overall Died | 21 (8.9) |
 Alive With Disease | 6 (2.5) |
 Alive With No Disease | 207 (87.7) |
 Alive Disease Status Unknown | 2 (0.8) |
 Overall Alive | 215 (91.1) |